Satish Govindaraj, MD
Otolaryngology · New York, NYNPI 1205871365
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (31.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Neurent Medical Limited at 48.8% of the total. Reporting peaked in 2023 at $15,116 and has fallen 65.5% since, to $5,215 in 2025. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $225.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurent Medical Limited$19K
- Olympus Corporation Of The Americas$11K
- Stryker$2K
- Medtronic$2K
- Acclarent, Inc$1K
- Olympus Corporation$1K
- plus $3K from 10 others
What the payments were for
- Consulting fees$12,33831%
- Travel & lodging$6,36216%
- Food & beverage$10,55827%
- Education$10,20026%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurent Medical Limited | 31 | $19,271 |
| Olympus Corporation Of The Americas | 23 | $11,469 |
| Stryker | 19 | $1,628 |
| Medtronic(2 entities) | 31 | $1,610 |
| Acclarent, Inc | 19 | $1,442 |
| Olympus Corporation | 1 | $1,063 |
| Intersect ENT, Inc. | 5 | $659 |
| Sanofi | 17 | $652 |
| Regeneron Healthcare Solutions, Inc. | 13 | $532 |
| Optinose US, Inc. | 6 | $487 |
| Integra Lifesciences Corporation | 3 | $322 |
| Aerin Medical Inc. | 3 | $123 |
| Arrinex, Inc. | 1 | $100 |
| Spirair, Inc. | 1 | $49 |
| GSK | 1 | $34 |
| Alk-abello, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROMARK Radiofrequency Console$18,282
- NEUROMARK Device$14,557
- Olympus ENT Instruments$11,401
- Celon System$11,401
- Olympus Rhinology Instruments$10,520
- PK Diego$10,338
- NEUROMARK System$4,236
- Olympus ENT Fiber Scopes$1,063
- Olympus Captial Accessories$1,063
- MULTIDEBRIDER HANDPIECE, ANGLED DIEGO ELITE$850
- TruDi Nav Cable$745
- TruDi Navigation System$603
- NEUROMARK Radiofrequency Generator$511
- PROPEL$493
- DUPIXENT$492
- FUSION$450
- STEALTHSTATION S8 PLATFORM$415
- SCOPIS ENT$412
- Xhance$344
- Acclarent Aera$290
How this compares
$39,458 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide | 76 | $12,836 |
| XhanceFluticasone Propionate | 14 | $9,495 |
| Ipratropium Bromide | 159 | $3,952 |
| Mometasone Furoate | 30 | $3,845 |
| Azelastine Hcl | 154 | $3,104 |
| Gentamicin Sulfate | 32 | $1,874 |
| Fluticasone Propionate | 135 | $1,472 |
| Famotidine | 103 | $1,233 |
| Mupirocin | 83 | $951 |
| Doxycycline Hyclate | 65 | $614 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 54 | $578 |
| Omeprazole | 52 | $550 |
| Methylprednisolone | 16 | $232 |
| Azithromycin | 35 | $212 |
| Levocetirizine Dihydrochloride | 13 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $487 | $9,49514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 otolaryngology providers in New York.
Other otolaryngology in New York
- Roheen RaithathaNew York$830K
- Dennis KrausNew York$159K
- Anthony DelsignoreNew York$89K
- Lawrence LustigNew York$33K
- Justin GolubNew York$30K
- Brett MilesNew York$30K
- David HiltzikNew York$25K
- Milan AminNew York$23K
- Ashutosh KackerNew York$20K
- Michael PitmanNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.